<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Front Nutr</journal-id><journal-id journal-id-type="publisher-id">Front. Nutr.</journal-id><journal-title-group><journal-title>Frontiers in Nutrition</journal-title></journal-title-group><issn pub-type="epub">2296-861X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013166</article-id><article-id pub-id-type="pmc">PMC11860086</article-id><article-id pub-id-type="doi">10.3389/fnut.2025.1527717</article-id><article-categories><subj-group subj-group-type="heading"><subject>Nutrition</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Serum alpha-1 acid glycoprotein and gallstone risk in US adult women: a cross-sectional analysis of the NHANES</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Xiaocheng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2893237/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Peiling</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2967352/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Hepatopancreatobiliary Surgery, Third Affiliated Hospital of Zunyi Medical University (The First People&#x02019;s Hospital of Zunyi)</institution>, <addr-line>Zunyi</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Medical Equipment, Third Affiliated Hospital of Zunyi Medical University (The First People&#x02019;s Hospital of Zunyi)</institution>, <addr-line>Zunyi</addr-line>, <country>China</country></aff><author-notes><fn id="fn0002" fn-type="edited-by"><p>Edited by: Sepehr Khosravi, Tehran University of Medical Sciences, Iran</p></fn><fn id="fn0003" fn-type="edited-by"><p>Reviewed by: Ali Golestani, Tehran University of Medical Sciences, Iran</p><p>Hiroshi Ito, Tokyo Medical University Ibaraki Medical Center, Japan</p></fn><corresp id="c001">*Correspondence: Xiaocheng Li, <email>xiaocheng_li@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1527717</elocation-id><history><date date-type="received"><day>19</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Li and He.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Li and He</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec id="sec1"><title>Background</title><p>Gallstone disease, a common biliary disorder, is linked to inflammation and immune responses. However, the association between serum alpha-1 acid glycoprotein (AGP), a key inflammatory marker, and gallstone risk remains underexplored.</p></sec><sec id="sec2"><title>Methods</title><p>Data from the National Health and Nutrition Examination Survey (NHANES) 2017&#x02013;2020 and 2021&#x02013;2023&#x0202f;cycles were analyzed. Gallstone disease was determined by self-reported physician diagnosis. Serum AGP levels were measured using a high-sensitivity turbidimetric immunoassay. Weighted logistic regression, subgroup analyses, smoothed curve analysis, and multiple imputation were used to examine the relationship between AGP and gallstone risk.</p></sec><sec id="sec3"><title>Results</title><p>This cross-sectional analysis included 1,903 adult women in the U.S. aged 20&#x02013;49. After adjusting for all covariates, serum AGP levels were positively associated with gallstone risk (OR: 3.07; 95% CI: 1.16, 8.11; <italic>p</italic>&#x0202f;=&#x0202f;0.036). Compared to the first tertile (T1), the third AGP tertile (T3) had an OR of 1.87 (95% CI: 1.11, 3.14; <italic>p</italic>&#x0202f;=&#x0202f;0.030). Smoothed curve analysis indicated a positive relationship between AGP and gallstone risk. Subgroup analyses consistently demonstrated this positive association across various demographic and clinical categories, with significant interactions observed for the ratio of family income to poverty. Sensitivity analyses using multiple imputation further supported the conclusion that AGP was associated with increased gallstone risk.</p></sec><sec id="sec4"><title>Conclusion</title><p>AGP is significantly associated with an increased risk of gallstones in U.S. adult women, suggesting its potential as a biomarker for risk stratification. Further research is needed to elucidate the underlying mechanisms and potential causal relationships.</p></sec></abstract><kwd-group><kwd>alpha-1 acid glycoprotein</kwd><kwd>gallstone</kwd><kwd>cross-sectional analysis</kwd><kwd>NHANES</kwd><kwd>inflammation</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="3"/><equation-count count="0"/><ref-count count="27"/><page-count count="9"/><word-count count="5690"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Clinical Nutrition</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><label>1</label><title>Introduction</title><p>Gallstone disease represents a prevalent disorder of the biliary system, influenced by multiple mechanisms including genetic predisposition, lifestyle factors, and metabolic abnormalities (<xref rid="ref1" ref-type="bibr">1</xref>&#x02013;<xref rid="ref3" ref-type="bibr">3</xref>). Common risk factors for gallstones include being female, older age, type 2 diabetes, non-alcoholic fatty liver disease, obesity, and rapid weight loss (<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref>). Gallstones are typically classified as either cholesterol or pigment stones, with cholesterol stones being the most common. Although the exact mechanism of gallstone formation remains unclear, it is thought to primarily involve genetic predisposition, cholesterol crystallization, and bile supersaturation (<xref rid="ref6" ref-type="bibr">6</xref>). Recent research has increasingly focused on the roles of inflammation and the immune system in the pathogenesis of gallstones (<xref rid="ref7" ref-type="bibr">7</xref>, <xref rid="ref8" ref-type="bibr">8</xref>). Serum biomarkers of inflammation and immune modulation have emerged as critical indicators in this area of study, garnering significant attention.</p><p>Alpha-1 acid glycoprotein (AGP), also known as orosomucoid, is a heavily glycosylated glycoprotein that plays a pivotal role in inflammation and immune responses (<xref rid="ref9" ref-type="bibr">9</xref>, <xref rid="ref10" ref-type="bibr">10</xref>). Its expression levels significantly increase during both acute and chronic inflammatory processes, such as those observed in cancer, obesity, infection, and cardiovascular disease, reflecting alterations in the body&#x02019;s inflammatory status and immune activity. Metabolic conditions, characterized by chronic systemic inflammation (<xref rid="ref11" ref-type="bibr">11</xref>), are believed to play a central role in gallstone formation by disrupting bile acid homeostasis, increasing cholesterol saturation in bile, and impairing gallbladder motility (<xref rid="ref12" ref-type="bibr">12</xref>). A study has suggested that AGP may have an impact on bile acid metabolism (<xref rid="ref13" ref-type="bibr">13</xref>). Therefore, there appears to be a potential association between AGP and gallstones, which may be mediated by its impact on bile acid metabolism and chronic inflammation induced by metabolic dysregulation. However, research on the relationship between AGP and gallstones is limited and somewhat inconsistent. A case&#x02013;control study has suggested a positive correlation between serum AGP levels and gallstones (<xref rid="ref14" ref-type="bibr">14</xref>). In contrast, another study involving bile samples from 12 gallstone patients has found no effect of AGP on concanavalin A activity, raising questions about AGP&#x02019;s role in gallstone formation (<xref rid="ref15" ref-type="bibr">15</xref>). Thus, elucidating the relationship between AGP and gallstones remains of significant importance.</p><p>This study will investigate the association between AGP and gallstone prevalence in women using data from the National Health and Nutrition Examination Survey (NHANES) 2017&#x02013;2020 and 2021&#x02013;2023&#x0202f;cycles. Weighted logistic regression, subgroup analyses, and smoothed curve analysis will be conducted to explore this relationship. Multiple imputation (MI) will also be performed to validate the robustness of the findings.</p></sec><sec sec-type="methods" id="sec6"><label>2</label><title>Methods</title><sec id="sec7"><label>2.1</label><title>Research design and participants</title><p>The National Center for Health Statistics (NCHS) administers the NHANES program, which collects comprehensive health data from a representative sample of adults and children through interviews, physical examinations, and laboratory analyses. The NCHS Institutional Review Board approved the study protocol, and informed consent was obtained from all participants. Detailed information and access to the data are available on the NHANES website.<xref rid="fn0001" ref-type="fn"><sup>1</sup></xref></p><p>The study population was limited to females aged 20&#x02013;49&#x0202f;years for several reasons. On one hand, AGP measurements in the NHANES dataset were only available for females aged 12&#x02013;49&#x0202f;years and children aged 1&#x02013;5&#x0202f;years during the 2017&#x02013;2020 and 2021&#x02013;2023&#x0202f;cycles, while males were not included in the AGP measurements, representing a limitation of the dataset. On the other hand, the gallstone questionnaire, which was used to identify participants&#x02019; gallstone history, was only administered to individuals aged 20&#x0202f;years and older.</p><p>Of the initial 27,493 enrollees, 10,452 were excluded because they were under 20&#x0202f;years of age and therefore did not complete the gallstone questionnaire. Further exclusions included 128 participants who were pregnant, 42 participants who either refused to answer or were unsure about their gallstone history, 14,100 who lacked serum AGP test results, and 868 participants with incomplete data on key covariates. After these exclusions, the final analytic sample comprised 1,903 participants. The selection process is illustrated in <xref rid="fig1" ref-type="fig">Figure 1</xref>, and <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 1</xref> provides details on missing data for key covariates.</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Flowchart of participant selection. The NHANES 2017&#x02013;2020 and 2021&#x02013;2023&#x0202f;cycles initially included 27,493 participants. Following the application of inclusion and exclusion criteria, 1,903 participants were ultimately retained for the final analysis.</p></caption><graphic xlink:href="fnut-12-1527717-g001" position="float"/></fig></sec><sec id="sec8"><label>2.2</label><title>Definition of gallstone</title><p>Participants were assessed for the presence of gallstones by asking, &#x0201c;Has a doctor ever told you that you have gallstones?&#x0201d; Individuals who answered &#x0201c;Yes&#x0201d; were categorized as having gallstones, while those who answered &#x0201c;No&#x0201d; were categorized as not having gallstones.</p></sec><sec id="sec9"><label>2.3</label><title>Measurement of AGP</title><p>AGP levels were measured in serum samples as part of the NHANES 2017&#x02013;2020 and 2021&#x02013;2023 cycles using a high-sensitivity turbidimetric immunoassay. This method involves the reaction of AGP in the sample with specific antibodies, leading to the formation of antigen&#x02013;antibody complexes that cause turbidity, which is then quantitatively measured. The assay was performed using a clinical chemistry analyzer, and results were standardized against known controls to ensure accuracy. This robust method allows for the precise quantification of AGP, which is crucial for assessing its association with various health outcomes, including gallstone formation.</p></sec><sec id="sec10"><label>2.4</label><title>Identification of covariates</title><p>The statistical model incorporated the following variables as covariates based on previous research (<xref rid="ref16" ref-type="bibr">16</xref>&#x02013;<xref rid="ref18" ref-type="bibr">18</xref>): age (years), race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Other), level of education (less than high school, high school, college or above), ratio of family income to poverty (&#x0003c;1.3, 1.3&#x02013;3.5, and &#x0003e;3.5), obesity, alcohol intake, sedentary activity, total cholesterol, hs-CRP, total energy intake, total fiber intake, total fat intake, total cholesterol intake, total moisture intake, and history of smoking, diabetes, and hypertension.</p><p>Age was divided into two categories: 20&#x02013;39&#x0202f;years and 40&#x02013;49&#x0202f;years.</p><p>Diabetes was identified based on an HbA1c level of &#x02265;6.5%, a self-reported diabetes diagnosis, a history of using antidiabetic medications, or fasting blood glucose levels of &#x02265;7&#x0202f;mmol/L.</p><p>Hypertension was defined by a mean systolic blood pressure of &#x02265;140&#x0202f;mmHg, a mean diastolic blood pressure of &#x02265;90&#x0202f;mmHg, or a self-reported diagnosis of hypertension.</p><p>Obesity was determined as a body mass index (BMI) of &#x02265;30&#x0202f;kg/m<sup>2</sup>.</p><p>Alcohol intake was assessed using responses to two specific questionnaire items: ALQ121, which asked, &#x0201c;In the past 12&#x0202f;months, how often did you drink alcoholic beverages?&#x0201d; and ALQ131, which queried, &#x0201c;During the past 12&#x0202f;months, on days when you consumed alcoholic beverages, how many drinks did you typically have?&#x0201d; Participants who reported consuming 12 or more alcoholic drinks per year were classified as alcohol consumers.</p><p>Individuals classified as smokers if they had smoked at least 100 cigarettes in their lifetime.</p><p>Total cholesterol levels and hs-CRP were derived from laboratory test results.</p><p>Sedentary activity was assessed using the NHANES questionnaire, which recorded the self-reported average daily time spent in sedentary behaviors, including activities such as sitting and watching television or using a computer, measured in minutes per day.</p><p>Total energy intake, total fiber intake, total fat intake, total cholesterol intake, and total moisture intake were derived from the first 24-h dietary recall interview conducted by NHANES. Participants reported all foods and beverages consumed in the previous 24&#x0202f;h, and these data were subsequently processed to quantify the total intake of each nutrient for the first day.</p></sec><sec id="sec11"><label>2.5</label><title>Statistical methods</title><p>Two-sided statistical tests were conducted, with significance set at <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05. All analyses were performed using R version 4.4.0. The NHANES official website recommends the use of appropriate sampling weights for statistical analysis and provides detailed guidance on how to apply these weights. In this study, the specific sample weights were used, as AGP data were measured in participants aged 3&#x02013;5&#x0202f;years and females aged 12&#x02013;49&#x0202f;years. The &#x0201c;survey&#x0201d; package in R was utilized to account for the NHANES complex sampling design, including weights, strata, and primary sampling units (PSUs), ensuring accurate variance estimation and nationally representative results.</p><p>Baseline characteristics were analyzed using the &#x0201c;svyCreateTableOne&#x0201d; function, which automatically applies survey-weighted statistical methods. Unweighted data were generated using the &#x0201c;CreateTableOne&#x0201d; function. Continuous variables are presented as weighted means with standard deviations, while categorical variables are presented as unweighted counts with weighted percentages. All statistical tests, including normality tests and non-parametric tests for continuous variables that did not meet the normality assumption, were performed using survey-weighted methods. An overall summary across all groups was also provided.</p><p>In accordance with STROBE guidelines (<xref rid="ref19" ref-type="bibr">19</xref>), three weighted multivariable regression models were constructed. Model 1 was unadjusted for any covariates. Model 2 was adjusted for age, race/ethnicity, level of education, and the ratio of family income to poverty. Model 3 was adjusted for all potential covariates. Potential collinearity among variables included in the complete model (Model 3) was assessed using generalized variance inflation factors (GVIFs) with adjustments for degrees of freedom. The complete GVIF results for all variables are provided in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 2</xref>. While some variables, such as ratio of family income to poverty (2.64), total energy intake (4.36), and total fat intake (4.93), exceeded the commonly accepted threshold of &#x0221a;5 (approximately 2.236), these were not central to the primary research objective. Furthermore, even when total energy intake or total fat intake was excluded from the model, the odds ratio (OR), 95% confidence interval (CI), and <italic>p</italic>-values for the association between AGP and gallstone risk showed only slightly changes. Thus, overall multicollinearity was not considered a significant concern for evaluating the association between AGP and gallstone risk.</p><p>Subgroup analyses were performed using weighted multivariate regression analysis for all categorical variables. Interaction terms were added to the models, and the log-likelihood ratio test was used to examine heterogeneity in associations across subgroups. A smoothed curve was generated to identify the dose&#x02013;response relationship between AGP and gallstone risk using generalized additive models (GAM) via the &#x0201c;mgcv&#x0201d; package in R. GAM was chosen for its ability to model non-linear relationships flexibly using penalized regression splines. Non-linearity was assessed by comparing the Akaike information criterion (AIC) values of the GAM and linear models. Additionally, the smoothed curves were visually inspected for deviations from linearity to further confirm the presence of non-linear relationships.</p><p>To mitigate bias due to missing data, MI was performed using the &#x0201c;MICE&#x0201d; package in R software (<xref rid="ref20" ref-type="bibr">20</xref>). The imputation model included variables listed in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 1</xref>, selected based on the variables included in model 3 described earlier. MI was performed using predictive mean matching (PMM) with five imputed datasets (m&#x0202f;=&#x0202f;5) and 20 iterations to ensure algorithm convergence. Diagnostics, including density plots and trace plots, were performed to validate the stability and convergence of imputed values. The results from the imputed datasets were combined using Rubin&#x02019;s rules to account for within- and between-imputation variability.</p></sec></sec><sec sec-type="results" id="sec12"><label>3</label><title>Results</title><sec id="sec13"><label>3.1</label><title>Baseline characteristics</title><p><xref rid="tab1" ref-type="table">Table 1</xref> summarizes the baseline characteristics of the study population across tertiles of AGP, adjusted for survey weights. Among the 1,903 participants, gallstones were identified in 185 individuals, corresponding to a sample-weighted prevalence of 9.9%. The weighted tertile ranges for AGP were T1 [0.261&#x02013;0.674], T2 [0.674&#x02013;0.880], and T3 [0.880&#x02013;2.020]. Significant differences were observed among the weighted AGP tertile groups in terms of education level, ratio of family income to poverty, smoking history, obesity, total cholesterol, total fiber intake, hs-CRP, history of diabetes, history of hypertension, and prevalence of gallstones (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05).</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics by AGP tertiles from the National Health and Nutrition Examination Survey (NHANES) 2017&#x02013;2020.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="3" colspan="1">Characteristics</th><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="3" rowspan="1">AGP tertiles</th><th align="center" valign="top" rowspan="3" colspan="1">
<italic>p</italic>
</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Overall</th><th align="center" valign="top" rowspan="1" colspan="1">T1</th><th align="center" valign="top" rowspan="1" colspan="1">T2</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1"><italic>N</italic>&#x0202f;=&#x0202f;1903</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>&#x0202f;=&#x0202f;620</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>&#x0202f;=&#x0202f;622</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>&#x0202f;=&#x0202f;661</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.239</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20&#x02013;39</td><td align="center" valign="middle" rowspan="1" colspan="1">1,242 (67.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">425 (70.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">407 (65.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">410 (66.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40&#x02013;49</td><td align="center" valign="middle" rowspan="1" colspan="1">661 (32.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">195 (29.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">215 (34.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">251 (34.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Race/Ethnicity, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.283</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Non-Hispanic White</td><td align="center" valign="middle" rowspan="1" colspan="1">804 (58.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">244 (57.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">246 (56.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">314 (60.4)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Non-Hispanic Black</td><td align="center" valign="middle" rowspan="1" colspan="1">384 (12.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">101 (11.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">131 (12.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">152 (14.5)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">715 (28.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">275 (31.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">245 (30.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">195 (25.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Less than high school</td><td align="center" valign="middle" rowspan="1" colspan="1">215 (7.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (6.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (9.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">71 (7.5)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">High school</td><td align="center" valign="middle" rowspan="1" colspan="1">331 (19.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (13.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">113 (21.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">143 (25.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">College or above</td><td align="center" valign="middle" rowspan="1" colspan="1">1,357 (72.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">486 (80.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">424 (69.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">447 (67.4)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ratio of family income to poverty, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">586 (23.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">147 (18.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">205 (25.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">234 (26.4)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">1.3&#x02013;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">690 (35.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">207 (31.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">221 (33.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">262 (41.6)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">627 (41.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">266 (49.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">196 (41.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">165 (32.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Alcohol intake, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.279</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">821 (38.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">235 (35.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">287 (39.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">299 (41.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1,082 (61.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">385 (64.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">335 (60.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">362 (58.9)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diabetes, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1738 (92.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">599 (97.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">562 (92.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">577 (88.9)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">165 (7.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (2.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">60 (7.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">84 (11.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hypertension, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1,542 (83.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">542 (89.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">506 (84.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">494 (77.9)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">361 (16.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">78 (10.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">116 (15.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">167 (22.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Obesity, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1,057 (58.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">529 (85.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">346 (60.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">182 (30.7)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">846 (41.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">91 (15.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">276 (39.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">479 (69.3)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1,304 (68.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">480 (78.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">434 (67.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">390 (60.9)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">599 (31.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">140 (22.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">188 (32.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">271 (39.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gallstones, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1718 (90.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">589 (95.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">563 (90.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">566 (84.8)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">185 (9.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (4.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (9.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">95 (15.2)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total cholesterol, mmol/L</td><td align="center" valign="middle" rowspan="1" colspan="1">4.72 (0.90)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.59 (0.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.79 (0.92)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.79 (0.93)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sedentary activity, minutes</td><td align="center" valign="middle" rowspan="1" colspan="1">360.59 (206.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">356.97 (200.31)</td><td align="center" valign="middle" rowspan="1" colspan="1">346.06 (201.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">378.91 (215.35)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.080</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total energy intake, kcal</td><td align="center" valign="middle" rowspan="1" colspan="1">1888.72 (798.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">1920.85 (791.63)</td><td align="center" valign="middle" rowspan="1" colspan="1">1827.74 (813.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">1917.90 (786.44)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.198</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total fiber intake, g</td><td align="center" valign="middle" rowspan="1" colspan="1">14.82 (10.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.00 (12.49)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.01 (8.59)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.44 (8.45)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total fat intake, g</td><td align="center" valign="middle" rowspan="1" colspan="1">79.52 (40.98)</td><td align="center" valign="middle" rowspan="1" colspan="1">82.19 (41.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">75.87 (39.94)</td><td align="center" valign="middle" rowspan="1" colspan="1">80.51 (41.69)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.114</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total cholesterol intake, g</td><td align="center" valign="middle" rowspan="1" colspan="1">275.48 (223.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">280.27 (230.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">286.98 (228.43)</td><td align="center" valign="middle" rowspan="1" colspan="1">259.06 (209.36)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.132</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total moisture intake, g</td><td align="center" valign="middle" rowspan="1" colspan="1">2843.58 (1320.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">2919.77 (1270.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">2802.41 (1351.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">2808.41 (1336.63)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.162</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hs-CRP, mg/L</td><td align="center" valign="middle" rowspan="1" colspan="1">4.30 (7.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.80 (3.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.06 (4.07)</td><td align="center" valign="top" rowspan="1" colspan="1">8.07 (9.78)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AGP, g/L</td><td align="center" valign="top" rowspan="1" colspan="1">0.79 (0.23)</td><td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.78 (0.06)</td><td align="center" valign="top" rowspan="1" colspan="1">1.06 (0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>Continuous variables were presented as weighted means with standard deviations. Means, percentages, and AGP tertiles were adjusted for the survey weights of the National Health and Nutrition Examination Survey (NHANES). AGP, alpha-1 acid glycoprotein; hs-CRP, high-sensitivity C-reactive protein.</p></table-wrap-foot></table-wrap></sec><sec id="sec14"><label>3.2</label><title>Association between AGP and gallstone risk</title><p>The association between AGP and the risk of gallstones was examined using three different models, adjusting for various confounders. The results were presented in <xref rid="tab2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Association between AGP and gallstone risk.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Exposure</th><th align="center" valign="top" colspan="2" rowspan="1">Model 1</th><th align="center" valign="top" colspan="2" rowspan="1">Model 2</th><th align="center" valign="top" colspan="2" rowspan="1">Model 3</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AGP (continuous)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.35 (3.78, 14.29)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">6.88 (3.52, 13.45)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">3.07 (1.16, 8.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td></tr><tr><td align="left" valign="middle" colspan="7" rowspan="1">Tertiles of AGP</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1, [0.261&#x02013;0.674]</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref.</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Ref.</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Ref.</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T2, [0.674&#x02013;0.880]</td><td align="center" valign="middle" rowspan="1" colspan="1">2.28 (1.30, 4.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">2.23 (1.25, 3.97)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td><td align="center" valign="middle" rowspan="1" colspan="1">1.53 (0.86, 2.69)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.162</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T3, [0.880&#x02013;2.020]</td><td align="center" valign="middle" rowspan="1" colspan="1">3.73 (2.36, 5.87)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">3.56 (2.28, 5.57)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.87 (1.11, 3.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td></tr></tbody></table><table-wrap-foot><p>Model 1: Unadjusted. Model 2: Adjusted for age, race/ethnicity, education, ratio of family income to poverty. Model 3: Adjusted for age, race/ethnicity, education, ratio of family income to poverty, alcohol intake, obesity, hypertension, diabetes, smoking, sedentary activity, total cholesterol, hs-CRP, total energy intake, total fiber intake, total fat intake, total cholesterol intake, total moisture intake. All results were adjusted for the survey weights of the National Health and Nutrition Examination Survey (NHANES). AGP, alpha-1 acid glycoprotein; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio; CI, confidence interval.</p></table-wrap-foot></table-wrap><p>After adjusting for all covariates (Model 3), AGP, treated as a continuous variable, was still positively associated with gallstone risk (OR: 3.07; 95% CI: 1.16&#x02013;8.11; <italic>p</italic>&#x0202f;=&#x0202f;0.036). Participants in the highest AGP tertile (T3) remained significantly associated with gallstone risk, with an OR of 1.87 (95% CI: 1.11&#x02013;3.14; <italic>p</italic>&#x0202f;=&#x0202f;0.030), compared to those in the lowest tertile (T1).</p><p>Smoothed curve fitting by the GAM displayed positive relationship between AGP and gallstone risk (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Smoothed curve analysis between AGP and gallstone risk by GAM. The red solid line represents the relationship between AGP and gallstone risk, while the dashed line indicates the 95% confidence interval (CI).</p></caption><graphic xlink:href="fnut-12-1527717-g002" position="float"/></fig></sec><sec id="sec15"><label>3.3</label><title>Subgroup analyses</title><p>Subgroup analysis revealed a positive association between higher levels of AGP and the risk of gallstone in several clinical categories (<xref rid="tab3" ref-type="table">Table 3</xref>). Significant associations were observed in older adults aged 40&#x02013;59&#x0202f;years, Non-Hispanic White individuals. Additionally, those with college or above, ratio of family income to poverty &#x0003e;3.5, no hypertension, no diabetes, alcohol consumers and smokers showed a significant positive correlation between higher AGP and gallstone risk (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05).</p><table-wrap position="float" id="tab3"><label>Table 3</label><caption><p>Subgroup analyses for the association between AGP and gallstone risk.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="3" colspan="1">Subgroups</th><th align="center" valign="top" colspan="3" rowspan="1">Tertiles of AGP</th><th align="center" valign="top" rowspan="3" colspan="1">
<italic>p for interaction</italic>
</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">T1</th><th align="center" valign="top" rowspan="1" colspan="1">T2</th><th align="center" valign="top" rowspan="1" colspan="1">T3</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Ref</th><th align="center" valign="top" rowspan="1" colspan="1">OR (95%CI) <italic>p</italic></th><th align="center" valign="top" rowspan="1" colspan="1">OR (95%CI) <italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.704</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20&#x02013;39</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.98 (0.48, 2.00) 0.954</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.11 (0.52, 2.38) 0.788</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40&#x02013;59</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.23 (0.99, 5.04) 0.068</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>3.17 (1.28, 7.86) 0.022</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Race/Ethnicity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Non-Hispanic White</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.52 (0.47, 4.92) 0.494</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>3.10 (1.26, 7.66) 0.025</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Non-Hispanic Black</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.60 (0.27, 9.63) 0.617</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.52 (0.08, 3.38) 0.513</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.22 (0.64, 2.32) 0.555</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.75 (0.33, 1.71) 0.508</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.685</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Less than high school</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.68 (0.12, 3.84) 0.670</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.62 (0.16, 2.42) 0.505</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">High school</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.49 (0.15, 1.63) 0.265</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.44 (0.10, 1.89) 0.289</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">College or above</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.92 (0.90, 4.11) 0.108</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>2.45 (1.41, 4.26) 0.005</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ratio of family income to poverty</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.011</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.34 (0.12, 0.95) 0.053</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.53 (0.22, 1.25) 0.163</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">1.3&#x02013;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.95 (0.85, 10.21) 0.103</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.07 (0.74, 12.82) 0.139</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.84 (0.67, 5.03) 0.251</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>3.54 (1.42, 8.83) 0.013</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.600</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.74 (0.27, 2.05) 0.573</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.60 (0.18, 1.95) 0.408</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.61 (0.79, 3.27) 0.206</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>2.32 (1.22, 4.40) 0.019</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diabetes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.388</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.78 (0.44, 17.42) 0.300</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.24 (0.46, 10.99) 0.344</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.41 (0.77, 2.57) 0.279</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>1.98 (1.14, 3.42) 0.025</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Obesity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.397</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.88 (0.84, 4.21) 0.143</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.48 (1.00, 6.17) 0.065</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.82 (0.38, 1.76) 0.613</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.06 (0.53, 2.15) 0.869</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Alcohol intake</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.742</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.57 (0.62, 4.02) 0.354</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>2.26 (1.27, 4.04) 0.012</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.34 (0.62, 2.91) 0.466</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.28 (0.44, 3.76) 0.653</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.103</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.69 (0.58, 4.98) 0.351</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>3.31 (1.20, 9.09) 0.032</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.43 (0.78, 2.61) 0.262</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.23 (0.60, 2.52) 0.582</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Results were adjusted for age, race/ethnicity, education, ratio of family income to poverty, alcohol intake, obesity, hypertension, diabetes, smoking, sedentary activity, total cholesterol, hs-CRP, total energy intake, total fiber intake, total fat intake, total cholesterol intake, total moisture intake, except for the variable itself. All analyses were adjusted for the survey weights of the National Health and Nutrition Examination Survey (NHANES). AGP, alpha-1 acid glycoprotein; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio; CI, confidence interval. The bolded values represent subgroups with statistical significance.</p></table-wrap-foot></table-wrap><p>Potential subgroup interactions were assessed using the likelihood ratio test. Among all subgroups, only the ratio of family income to poverty showed a significant interaction (<italic>p for interaction</italic>&#x0202f;&#x0003c;&#x0202f;0.05). No other significant interactions were observed across the subgroups. Multiple comparisons were not adjusted, as these analyses were exploratory and hypothesis-generating in nature.</p></sec><sec id="sec16"><label>3.4</label><title>Sensitivity analysis</title><p>A sensitivity analysis was conducted on the multiply imputed data to assess the robustness of the findings. The analysis divided the data into weighted tertiles based on AGP levels: T1 [0.261&#x02013;0.672], T2 [0.672&#x02013;0.880], and T3 [0.880&#x02013;2.760]. The results demonstrated that the estimates derived from the imputed data were consistent with those obtained from the original data (<xref rid="SM1" ref-type="supplementary-material">Supplementary Tables 3</xref>, <xref rid="SM1" ref-type="supplementary-material">4</xref>).</p></sec></sec><sec sec-type="discussion" id="sec17"><label>4</label><title>Discussion</title><p>This study analyzed data from the NHANES 2017&#x02013;2020 and 2021&#x02013;2023&#x0202f;cycles, focusing on the association between AGP levels and the risk of gallstones in a total of 1,903 female adult participants. Weighted logistic regression revealed a significant positive association between AGP levels and gallstone risk, even after adjusting for all covariates (OR: 3.07; 95% CI: 1.16&#x02013;8.11; <italic>p</italic>&#x0202f;=&#x0202f;0.036). Specifically, after full adjustment, compared to the first tertile (T1), participants in the third tertile (T3) showed a statistically significant elevated risk (OR: 1.87; 95% CI: 1.11&#x02013;3.14; <italic>p</italic>&#x0202f;=&#x0202f;0.030). Smoothed curve analysis revealed positive relationship between AGP and gallstone risk. Subgroup analyses further supported the positive association between higher AGP levels and gallstone risk across various demographic and clinical categories. Sensitivity analyses, including MI, confirmed the robustness of these findings.</p><p>Previous studies have suggested a positive correlation between AGP levels in bile and serum with gallstones, indicating that AGP in bile may influence the nucleation time of cholesterol stones (<xref rid="ref14" ref-type="bibr">14</xref>, <xref rid="ref21" ref-type="bibr">21</xref>). This study analyzed a larger and more representative sample from NHANES, specifically focusing on the association between AGP and gallstones in adult women. The results are consistent with previous findings, further supporting the role of AGP in gallstone formation.</p><p>As an inflammation-associated acute-phase protein, AGP may play a significant role in gallstone formation through several plausible biological mechanisms. Inflammatory processes are well-established contributors to gallstone pathogenesis, particularly within the context of metabolic syndrome, where chronic low-grade inflammation is a hallmark feature. Elevated AGP levels, which reflect systemic inflammation, could contribute to an immune environment that facilitates gallstone formation. Firstly, AGP is closely associated with cytokines such as IL-6 and TNF-&#x003b1;, which are critical mediators of chronic systemic inflammation (<xref rid="ref22" ref-type="bibr">22</xref>). These cytokines are known to impair gallbladder motility by disrupting smooth muscle function, leading to bile stasis, which is a key risk factor for gallstone formation (<xref rid="ref23" ref-type="bibr">23</xref>). Elevated AGP levels may serve as both a marker and a contributor to this inflammatory state, linking systemic inflammation to gallstone pathogenesis. Secondly, AGP may influence bile composition and metabolism, which are central to gallstone pathogenesis. Cholesterol supersaturation of bile is a primary driver of gallstone formation, and chronic inflammation disrupts hepatic bile acid regulation. AGP may interfere with nuclear receptor pathways, particularly farnesoid X receptor (FXR) (<xref rid="ref13" ref-type="bibr">13</xref>), a key regulator of bile acid synthesis via CYP7A1. Impaired FXR signaling, potentially exacerbated by elevated AGP levels, could result in decreased bile acid secretion and increased cholesterol saturation, fostering a bile environment conducive to cholesterol crystallization and gallstone formation. Finally, metabolic syndrome provides a relevant framework to understand the role of AGP in gallstone formation. Elevated AGP levels in metabolic syndrome likely reflect a state of chronic systemic inflammation driven by central obesity, insulin resistance, and dyslipidemia. Insulin resistance is particularly relevant, as it impairs hepatic bile acid synthesis and increases biliary cholesterol secretion (<xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref25" ref-type="bibr">25</xref>). Lee et al. (<xref rid="ref26" ref-type="bibr">26</xref>) found that excessive bile acids strongly induce AGP, which inhibits adipocyte differentiation and significantly suppresses the gene expression of adipogenic transcription factors, such as C/EBP&#x003b2;, KLF5, C/EBP&#x003b1;, and PPAR&#x003b3;. While this response may confer anti-obesity effects, it may also alter lipid metabolism in ways that predispose individuals to cholesterol supersaturation of bile. Thus, AGP may act as a mediator by linking metabolic dysfunction, chronic inflammation, and bile dysregulation, creating conditions favorable for gallstone formation.</p><p>Clinically, these findings highlight AGP as a potential biomarker for assessing gallstone risk, especially in women with other known risk factors. Our findings, after adjusting for hs-CRP, suggest that AGP could serve as an independent marker of gallstone risk beyond the general inflammatory markers currently used in clinical practice. However, further studies are needed to evaluate its predictive value and clinical utility, particularly in identifying individuals at higher risk who might benefit from targeted interventions.</p><sec id="sec18"><label>4.1</label><title>Strengths of this study</title><p>Firstly, utilizing data from NHANES 2017&#x02013;2020 and 2021&#x02013;2023, this study benefits from its national representativeness, making the findings generalizable to the broader U.S. adult population. Secondly, the study thoroughly adjusted for key demographic and lifestyle confounders, enhancing the reliability of the observed association between AGP and gallstone risk. Additionally, the study employed robust statistical methods, including weighted logistic regression and MI to validate the findings. Finally, this study systematically explores the link between AGP and gallstone risk in women, contributing to the understanding of this association and suggesting new avenues for future research.</p></sec><sec id="sec19"><label>4.2</label><title>Limitations</title><p>Firstly, the cross-sectional design limits causal inference, making it unclear whether elevated AGP levels contribute to gallstone formation or are a consequence of the disease. Secondly, gallstone disease was defined based on self-reported interview data rather than medical imaging or clinical diagnoses, which may introduce recall bias or misclassification. This limitation is inherent in large-scale population surveys like NHANES, and future studies should aim to use objective diagnostic measures, such as abdominal ultrasound, to confirm gallstone presence. Thirdly, while we adjusted for several key demographic and lifestyle confounders, other potential risk factors, such as fasting status and a history of biliary tract disease, were not comprehensively accounted for due to limitations in the dataset. These factors have been reported as important contributors to gallbladder-related conditions (<xref rid="ref27" ref-type="bibr">27</xref>) and may influence the observed association. Finally, the study&#x02019;s focus on American women aged 20&#x02013;49 restricts generalizability to men and other age groups. Expanding the study population in future research would provide a more comprehensive understanding of AGP&#x02019;s association with gallstone disease. Despite these limitations, identifying interventions to reduce AGP levels could have significant clinical implications, potentially aiding in gallstone prevention and management.</p></sec><sec id="sec20"><label>4.3</label><title>Future directions</title><p>Future longitudinal studies are needed to clarify causality and investigate AGP&#x02019;s biological role in gallstone formation. Specifically, prospective cohort studies incorporating objective outcome measures, such as imaging techniques (e.g., abdominal ultrasound), are essential to confirm the presence of gallstones. The inclusion of ultrasound data would address potential misclassification bias due to self-reported gallstone diagnoses. Furthermore, future studies should incorporate a broader panel of inflammatory and metabolic markers, such as interleukins, tumor necrosis factor-alpha (TNF-&#x003b1;), adiponectin, and lipid profiles, to disentangle the causal pathways underlying the AGP-gallstone association. These markers would provide a more comprehensive understanding of the interplay between systemic inflammation, bile metabolism, and gallstone pathogenesis. Finally, mechanistic studies using animal models or human bile samples could elucidate AGP&#x02019;s specific role in bile supersaturation, mucin secretion, and cholesterol crystallization. Identifying interventions to reduce AGP levels could have significant clinical implications, particularly for individuals at high risk for gallstone formation. Such interventions might include lifestyle modifications, anti-inflammatory therapies, or metabolic-targeted treatments, which warrant further exploration.</p></sec></sec><sec sec-type="conclusions" id="sec21"><label>5</label><title>Conclusion</title><p>AGP is significantly and positively associated with gallstone risk in U.S. female adults. These findings suggest that AGP may play a role in gallstone risk, highlighting the need for further research to explore the underlying mechanisms and to investigate these associations in different populations and settings.</p></sec></body><back><fn-group><fn id="fn0001"><p>
<sup>1</sup>
<ext-link xlink:href="https://www.cdc.gov/nchs/nhanes/index.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nhanes/index.htm</ext-link>
</p></fn></fn-group><sec sec-type="data-availability" id="sec22"><title>Data availability statement</title><p>Publicly available datasets were analyzed in this study. This data can be found here: <ext-link xlink:href="https://www.cdc.gov/nchs/nhanes/index.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nhanes/index.htm</ext-link>.</p></sec><sec sec-type="ethics-statement" id="sec23"><title>Ethics statement</title><p>The studies involving humans were approved by National Center for Health Statistics (NCHS) Institutional Review Board, Centers for Disease Control and Prevention (CDC), United States. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="sec24"><title>Author contributions</title><p>XL: Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Supervision, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. PH: Data curation, Formal analysis, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec26"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec27"><title>Generative AI statement</title><p>The author(s) declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec28"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec29"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fnut.2025.1527717/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnut.2025.1527717/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Table_1.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutt</surname><given-names>C</given-names></name><name><surname>Schl&#x000e4;fer</surname><given-names>S</given-names></name><name><surname>Lammert</surname><given-names>F</given-names></name></person-group>. <article-title>The treatment of gallstone disease</article-title>. <source>Dtsch Arztebl Int</source>. (<year>2020</year>) <volume>117</volume>:<fpage>148</fpage>&#x02013;<lpage>58</lpage>. doi: <pub-id pub-id-type="doi">10.3238/arztebl.2020.0148</pub-id>, PMID: <pub-id pub-id-type="pmid">32234195</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cort&#x000e9;s</surname><given-names>VA</given-names></name><name><surname>Barrera</surname><given-names>F</given-names></name><name><surname>Nervi</surname><given-names>F</given-names></name></person-group>. <article-title>Pathophysiological connections between gallstone disease, insulin resistance, and obesity</article-title>. <source>Obes Rev</source>. (<year>2020</year>) <volume>21</volume>:<fpage>e12983</fpage>. doi: <pub-id pub-id-type="doi">10.1111/obr.12983</pub-id>, PMID: <pub-id pub-id-type="pmid">31814283</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>E</surname><given-names>S</given-names></name><name><surname>Srikanth</surname><given-names>MS</given-names></name><name><surname>Shreyas</surname><given-names>A</given-names></name><name><surname>Desai</surname><given-names>S</given-names></name><name><surname>Mehdi</surname><given-names>S</given-names></name><name><surname>Gangadharappa</surname><given-names>HV</given-names></name><etal/></person-group>. <article-title>Recent advances, novel targets and treatments for cholelithiasis; a narrative review</article-title>. <source>Eur J Pharmacol</source>. (<year>2021</year>) <volume>908</volume>:<fpage>174376</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174376</pub-id>, PMID: <pub-id pub-id-type="pmid">34303667</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welbourn</surname><given-names>R</given-names></name><name><surname>Pournaras</surname><given-names>DJ</given-names></name></person-group>. <article-title>Bariatric surgery and prophylaxis against symptomatic gallstone disease</article-title>. <source>Lancet Gastroenterol Hepatol</source>. (<year>2021</year>) <volume>6</volume>:<fpage>972</fpage>&#x02013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2468-1253(21)00383-6</pub-id>, PMID: <pub-id pub-id-type="pmid">34715030</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Jepsen</surname><given-names>J</given-names></name></person-group>. <article-title>Gallstone disease: common questions and answers</article-title>. <source>Am Fam Physician</source>. (<year>2024</year>) <volume>109</volume>:<fpage>518</fpage>&#x02013;<lpage>24</lpage>. PMID: <pub-id pub-id-type="pmid">38905549</pub-id>
</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HH</given-names></name><name><surname>Portincasa</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>DQH</given-names></name></person-group>. <article-title>Effects of biliary phospholipids on cholesterol crystallization and growth in gallstone formation</article-title>. <source>Adv Ther</source>. (<year>2023</year>) <volume>40</volume>:<fpage>743</fpage>&#x02013;<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12325-022-02407-8</pub-id>, PMID: <pub-id pub-id-type="pmid">36602656</pub-id>
</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Liu</surname><given-names>MY</given-names></name><name><surname>Ma</surname><given-names>YX</given-names></name><name><surname>Wan</surname><given-names>QQ</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Diao</surname><given-names>XO</given-names></name><etal/></person-group>. <article-title>Inflammation-associated ectopic mineralization</article-title>. <source>Fundam Res</source>. (<year>2023</year>) <volume>3</volume>:<fpage>1025</fpage>&#x02013;<lpage>38</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.fmre.2022.04.020</pub-id>, PMID: <pub-id pub-id-type="pmid">38933004</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>JY</given-names></name><name><surname>Zhu</surname><given-names>XJ</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group>. <article-title>Research progress on the immune microenvironment of the gallbladder in patients with cholesterol gallstones</article-title>. <source>World J Gastrointest Surg</source>. (<year>2022</year>) <volume>14</volume>:<fpage>887</fpage>&#x02013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.4240/wjgs.v14.i9.887</pub-id>, PMID: <pub-id pub-id-type="pmid">36185563</pub-id>
</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingenbleek</surname><given-names>Y</given-names></name></person-group>. <article-title>Revisiting PINI scoring in light of recent biological advances</article-title>. <source>Nutrients</source>. (<year>2023</year>) <volume>15</volume>:<fpage>1846</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu15081846</pub-id>, PMID: <pub-id pub-id-type="pmid">37111065</pub-id>
</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>M</given-names></name></person-group>. <article-title>Into the labyrinth of the Lipocalin &#x003b1;1-acid glycoprotein</article-title>. <source>Front Physiol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>686251</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2021.686251</pub-id>, PMID: <pub-id pub-id-type="pmid">34168570</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohm</surname><given-names>TV</given-names></name><name><surname>Meier</surname><given-names>DT</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name><name><surname>Donath</surname><given-names>MY</given-names></name></person-group>. <article-title>Inflammation in obesity, diabetes and related disorders</article-title>. <source>Immunity</source>. (<year>2022</year>) <volume>55</volume>:<fpage>31</fpage>&#x02013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2021.12.013</pub-id>, PMID: <pub-id pub-id-type="pmid">35021057</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Chiang</surname><given-names>JYL</given-names></name></person-group>. <article-title>Bile acid signaling in metabolic disease and drug therapy</article-title>. <source>Pharmacol Rev</source>. (<year>2014</year>) <volume>66</volume>:<fpage>948</fpage>&#x02013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1124/pr.113.008201</pub-id>, PMID: <pub-id pub-id-type="pmid">25073467</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porez</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Prawitt</surname><given-names>J</given-names></name><name><surname>Gheeraert</surname><given-names>C</given-names></name><name><surname>Berrabah</surname><given-names>W</given-names></name><name><surname>Alexandre</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The hepatic orosomucoid/&#x003b1;1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR</article-title>. <source>Endocrinology</source>. (<year>2013</year>) <volume>154</volume>:<fpage>3690</fpage>&#x02013;<lpage>701</lpage>. doi: <pub-id pub-id-type="doi">10.1210/en.2013-1263</pub-id>, PMID: <pub-id pub-id-type="pmid">23861371</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thijs</surname><given-names>CT</given-names></name><name><surname>Groen</surname><given-names>AK</given-names></name><name><surname>Hovens</surname><given-names>M</given-names></name><name><surname>Mok</surname><given-names>KS</given-names></name></person-group>. <article-title>Risk of gallstone disease is associated with serum level of alpha-1-acid glycoprotein</article-title>. <source>Epidemiology</source>. (<year>1999</year>) <volume>10</volume>:<fpage>764</fpage>&#x02013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00001648-199911000-00019</pub-id>, PMID: <pub-id pub-id-type="pmid">10535793</pub-id>
</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruijn</surname><given-names>MA</given-names></name><name><surname>Mok</surname><given-names>KS</given-names></name><name><surname>Out</surname><given-names>T</given-names></name><name><surname>Tytgat</surname><given-names>GN</given-names></name><name><surname>Groen</surname><given-names>AK</given-names></name></person-group>. <article-title>Immunoglobulins and alpha 1-acid glycoprotein do not contribute to the cholesterol crystallization-promoting effect of concanavalin A-binding biliary protein</article-title>. <source>Hepatology</source>. (<year>1994</year>) <volume>20</volume>:<fpage>626</fpage>&#x02013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0270-9139(94)90097-3</pub-id>, PMID: <pub-id pub-id-type="pmid">8076920</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name><name><surname>Lan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The association between fat distribution and &#x003b1;1-acid glycoprotein levels among adult females in the United States</article-title>. <source>Lipids Health Dis</source>. (<year>2024</year>) <volume>23</volume>:<fpage>235</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12944-024-02223-9</pub-id>, PMID: <pub-id pub-id-type="pmid">39080765</pub-id>
</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><name><surname>You</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name></person-group>. <article-title>Investigating the association between blood cobalt and gallstones: a cross-sectional study utilizing NHANES data. Front</article-title>. <source>Public Health</source>. (<year>2024</year>) <volume>12</volume>:<fpage>12</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpubh.2024.1363815</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Leng</surname><given-names>K</given-names></name></person-group>. <article-title>Lipid accumulation product and gallstone risk in US adults: A cross-sectional analysis of NHANES 2017&#x02013;2020 data</article-title>. <source>PLoS One</source>. (<year>2024</year>) <volume>19</volume>:<fpage>e0315235</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0315235</pub-id>, PMID: <pub-id pub-id-type="pmid">39636931</pub-id>
</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Elm</surname><given-names>E</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Pocock</surname><given-names>SJ</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>PC</given-names></name><name><surname>Vandenbroucke</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>Lancet</source>. (<year>2007</year>) <volume>370</volume>:<fpage>1453</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61602-X</pub-id>, PMID: <pub-id pub-id-type="pmid">18064739</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>YS</given-names></name><name><surname>Gelman</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Yajima</surname><given-names>M</given-names></name></person-group>. <article-title>Multiple imputation with diagnostics (mi) in R: opening windows into the black box</article-title>. <source>J Stat Softw</source>. (<year>2011</year>) <volume>45</volume>:<fpage>1</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.18637/jss.v045.i02</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuutinen</surname><given-names>H</given-names></name><name><surname>Corradini</surname><given-names>SG</given-names></name><name><surname>J&#x000fc;ngst</surname><given-names>D</given-names></name><name><surname>Lange</surname><given-names>V</given-names></name><name><surname>Abei</surname><given-names>M</given-names></name><name><surname>Schwarzendrube</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Correlation between biliary&#x003b1;1-acid glycoprotein concentration and cholesterol crystal nucleation time in gallstone disease</article-title>. <source>Dig Dis Sci</source>. (<year>1995</year>) <volume>40</volume>:<fpage>1174</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF02065520</pub-id>, PMID: <pub-id pub-id-type="pmid">7781430</pub-id>
</mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>DF</given-names></name></person-group>. <article-title>Orosomucoid, an acute response protein with multiple modulating activities</article-title>. <source>J Physiol Biochem</source>. (<year>2015</year>) <volume>71</volume>:<fpage>329</fpage>&#x02013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13105-015-0389-9</pub-id>, PMID: <pub-id pub-id-type="pmid">25711902</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Kemp</surname><given-names>TJ</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Corbel</surname><given-names>A</given-names></name><name><surname>McGee</surname><given-names>EE</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The Association of Circulating Inflammation Proteins and Gallstone Disease</article-title>. <source>J Gastroenterol Hepatol</source>. (<year>2018</year>) <volume>33</volume>:<fpage>1920</fpage>&#x02013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jgh.14265</pub-id>, PMID: <pub-id pub-id-type="pmid">29671891</pub-id>
</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biddinger</surname><given-names>SB</given-names></name><name><surname>Haas</surname><given-names>JT</given-names></name><name><surname>Yu</surname><given-names>BB</given-names></name><name><surname>Bezy</surname><given-names>O</given-names></name><name><surname>Jing</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Hepatic insulin resistance directly promotes formation of cholesterol gallstones</article-title>. <source>Nat Med</source>. (<year>2008</year>) <volume>14</volume>:<fpage>778</fpage>&#x02013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nm1785</pub-id>, PMID: <pub-id pub-id-type="pmid">18587407</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portincasa</surname><given-names>P</given-names></name><name><surname>Di Ciaula</surname><given-names>A</given-names></name><name><surname>Bonfrate</surname><given-names>L</given-names></name><name><surname>Stella</surname><given-names>A</given-names></name><name><surname>Garruti</surname><given-names>G</given-names></name><name><surname>Lamont</surname><given-names>JT</given-names></name></person-group>. <article-title>Metabolic dysfunction-associated gallstone disease: expecting more from critical care manifestations</article-title>. <source>Intern Emerg Med</source>. (<year>2023</year>) <volume>18</volume>:<fpage>1897</fpage>&#x02013;<lpage>918</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11739-023-03355-z</pub-id>, PMID: <pub-id pub-id-type="pmid">37455265</pub-id>
</mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>JM</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Cox</surname><given-names>AR</given-names></name><name><surname>Hartig</surname><given-names>SM</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><etal/></person-group>. <article-title>The bile acid induced hepatokine orosomucoid suppresses adipocyte differentiation</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2021</year>) <volume>534</volume>:<fpage>864</fpage>&#x02013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.10.086</pub-id>, PMID: <pub-id pub-id-type="pmid">33168190</pub-id>
</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Okaya</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>R</given-names></name><name><surname>Shimojo</surname><given-names>N</given-names></name></person-group>. <article-title>Incidence and risk factors for hospital-acquired cholecystitis</article-title>. <source>J Hosp Infect</source>. (<year>2022</year>) <volume>128</volume>:<fpage>13</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhin.2022.07.003</pub-id>, PMID: <pub-id pub-id-type="pmid">35830937</pub-id>
</mixed-citation></ref></ref-list></back></article>